Skip to main content

Palmar Hyperhidrosis

2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Journey Medical
Journey MedicalAZ - Scottsdale
1 program
1
Glycopyrronium cloth, 2.4%Phase 21 trial
Active Trials
NCT03880266Completed72Est. May 2019
Atacama Therapeutics
Atacama TherapeuticsMA - Wellesley
1 program
1
dexmecamylaminePhase 22 trials
Active Trials
NCT04263623Unknown75Est. Sep 2021
NCT03404570Completed60Est. Jan 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Atacama Therapeuticsdexmecamylamine
Journey MedicalGlycopyrronium cloth, 2.4%
Atacama Therapeuticsdexmecamylamine

Clinical Trials (3)

Total enrollment: 207 patients across 3 trials

NCT04263623Atacama Therapeuticsdexmecamylamine

Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Start: Jan 2020Est. completion: Sep 202175 patients
Phase 2Unknown
NCT03880266Journey MedicalGlycopyrronium cloth, 2.4%

A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis

Start: Feb 2019Est. completion: May 201972 patients
Phase 2Completed
NCT03404570Atacama Therapeuticsdexmecamylamine

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Start: Dec 2017Est. completion: Jan 201960 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.